BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Dynavax Technologies Corporation 

2929 Seventh Street
Suite 100
Berkeley  California   94710  U.S.A.
Phone: 510-848-5100 Fax: 510-848-1379


View Clinical Trials from BioPharm Insight

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. Our Company’s lead product candidate is HEPLISAV ™, an Investigational adult hepatitis B vaccine designed to
enhance protection more rapidly and with fewer doses than current licensed vaccines.

Clinical-Sage Pipeline

Our Clinical-stage pipeline includes 3 product candidates for the prevention and treatment of infectious diseases.

• Phase 3 HEPLISAV ™ Hepatitis B Vaccine
• Autoimmunity/Inflammation—Glaxo Smith Kline (GSK)
• Asthma/COPD—Astra Zenica

Focused on Infectious Disease

Scientific expertise and proprietary technologies drive our discovery and development of novel Toll-like Receptor (TLR) based product
candidates. Our focus is on serious medical needs in the prevention and treatment of infectious diseases.

Leading Partners

Our partnerships with leading pharmaceutical companies, including GlaxoSmithKline and AstraZeneca. Our funding
agreements support our commitment discover and develop TLR-based products to address serious medical diseases.

Integrated European Subsidiary

Rhein Biotech. Our European subsidiary, manufactures hepatitis B surface antigen for our lead product HEPLISAV ™ Hepatitis B vaccine. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.

Join an organization with cutting edge science and an experienced team dedicated towards discovering and developing products to prevent and treat infectious diseases. We offer a work environment that fosters learning, respect, open communication, integration, collaboration, and team orientation. Our employees work hard together, have fun, and share in the Company’s accomplishments.

 Key Statistics


Web Site: Dynavax Technologies Corporation
Symbol: DVAX

 Company News
Dynavax Technologies Corporation (DVAX) Reports Second Quarter 2014 Financial Results And Safety And Pharmacodynamic Results For Asthma And Lupus Drug Candidates 8/7/2014 8:42:53 AM
Dynavax Technologies Corporation (DVAX) To Present At The William Blair 2014 Growth Stock Conference 6/10/2014 10:26:19 AM
Dynavax Technologies Corporation (DVAX) To Present At The Jefferies and Co. Global Healthcare Conference 6/3/2014 9:14:00 AM
Dynavax Technologies Corporation (DVAX) Reports First Quarter 2014 Financial Results 5/6/2014 9:32:55 AM
Dynavax Technologies Corporation (DVAX) Initiates Phase 3 Study Of HEPLISAV-B™ 4/16/2014 10:14:40 AM
Dynavax Technologies Corporation (DVAX) Reports Fourth Quarter And Year End 2013 Financial Results 3/11/2014 10:27:34 AM
Dynavax Technologies Corporation (DVAX) To Receive $5.4 Million Milestone 3/4/2014 9:55:17 AM
Dynavax Technologies Corporation (DVAX) To Present At The 34th Annual Cowen and Company Health Care Conference 3/3/2014 10:23:19 AM
Dynavax Technologies Corporation (DVAX) Announces Withdrawal Of European Marketing Application For HEPLISAV™ 2/18/2014 9:20:54 AM
Dynavax Technologies Corporation (DVAX) To Present At The 32nd Annual J.P. Morgan Healthcare Conference 1/13/2014 9:25:46 AM